Mitsuru Hashida

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1141166/publications.pdf

Version: 2024-02-01

317 papers 14,678 citations

65 h-index 98 g-index

329 all docs 329 docs citations

times ranked

329

13083 citing authors

#	Article	IF	CITATIONS
1	Advocation and advancements of EPR effect theory in drug delivery science: A commentary. Journal of Controlled Release, 2022, 346, 355-357.	4.8	10
2	Strictness and Transparency in Approval Process of Medical Products: Japanese Situation. Clinical Pharmacology and Therapeutics, 2021, 109, 290-290.	2.3	0
3	Evaluation of transgene expression characteristics and DNA vaccination against melanoma metastasis of an intravenously injected ternary complex with biodegradable dendrigraft poly-L-lysine in mice. Drug Delivery, 2021, 28, 542-549.	2.5	3
4	The Application of the <i>in-Situ</i> Hyperthermia Emission from Acoustic Nanodroplets for Theranostic Dual-Imaging and Antitumor Modalities. Biological and Pharmaceutical Bulletin, 2020, 43, 1141-1145.	0.6	0
5	Role of pharmacokinetic consideration for the development of drug delivery systems: A historical overview. Advanced Drug Delivery Reviews, 2020, 157, 71-82.	6.6	32
6	Development of a DNA Vaccine for Melanoma Metastasis by Inhalation Based on an Analysis of Transgene Expression Characteristics of Naked pDNA and a Ternary Complex in Mouse Lung Tissues. Pharmaceutics, 2020, 12, 540.	2.0	16
7	Effects of Tissue Pressure on Transgene Expression Characteristics via Renal Local Administration Routes from Ureter or Renal Artery in the Rat Kidney. Pharmaceutics, 2020, 12, 114.	2.0	7
8	Tissue suction-mediated gene transfer to the beating heart in mice. PLoS ONE, 2020, 15, e0228203.	1.1	3
9	Sialyl LewisX mimic-decorated liposomes for anti-angiogenic everolimus delivery to E-selectin expressing endothelial cells. RSC Advances, 2019, 9, 20518-20527.	1.7	5
10	Evaluation of the Theranostic Potential of Perfluorohexane-Based Acoustic Nanodroplets. Biological and Pharmaceutical Bulletin, 2019, 42, 2038-2044.	0.6	3
11	Development of mKO2 fusion proteins for real-time imaging and mechanistic investigation of the degradation kinetics of human liºBl± in living cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 190-198.	1.9	2
12	Binding and structure-kinetic relationship analysis of selective TLR4-targeted immunosuppressive self-assembling heparin nanoparticles. International Journal of Pharmaceutics, 2018, 552, 76-83.	2.6	7
13	Urokinase injection-triggered clearance enhancement of a 4-arm PEG-conjugated 64Cu-bombesin analog tetramer: A novel approach for the improvement of PET imaging contrast. International Journal of Pharmaceutics, 2018, 545, 206-214.	2.6	13
14	Use of Membrane Potential to Achieve Transmembrane Modification with an Artificial Receptor. Bioconjugate Chemistry, 2017, 28, 296-301.	1.8	5
15	Hexaphyrin as a Potential Theranostic Dye for Photothermal Therapy and ¹⁹ F Magnetic Resonance Imaging. ChemBioChem, 2017, 18, 951-959.	1.3	16
16	Quantitative prediction of ionization effect on human skin permeability. International Journal of Pharmaceutics, 2017, 522, 222-233.	2.6	13
17	The development of mechanically formed stable nanobubbles intended for sonoporation-mediated gene transfection. Drug Delivery, 2017, 24, 320-327.	2.5	25
18	Synthesis and Functional Characterization of Novel Sialyl LewisX Mimic-Decorated Liposomes for E-selectin-Mediated Targeting to Inflamed Endothelial Cells. Molecular Pharmaceutics, 2017, 14, 1528-1537.	2.3	23

#	Article	IF	Citations
19	An Evolutionary Search Algorithm for Covariate Models in Population Pharmacokinetic Analysis. Journal of Pharmaceutical Sciences, 2017, 106, 2407-2411.	1.6	11
20	InÂVitro Cellular Gene Delivery Employing a Novel Composite Material of Single-Walled Carbon Nanotubes Associated With Designed Peptides With Pegylation. Journal of Pharmaceutical Sciences, 2017, 106, 792-802.	1.6	5
21	High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases. Journal of Controlled Release, 2017, 266, 301-309.	4.8	34
22	Anti-inflammatory Effect of Self-assembling Glycol-Split Glycosaminoglycan-Stearylamine Conjugates in Lipopolysaccharide-Stimulated Macrophages. Biological and Pharmaceutical Bulletin, 2017, 40, 540-545.	0.6	8
23	Development of PEGylated Cysteine-Modified Lysine Dendrimers with Multiple Reduced Thiols To Prevent Hepatic Ischemia/Reperfusion Injury. Molecular Pharmaceutics, 2016, 13, 2867-2873.	2.3	23
24	Sustained Release of Mitomycin C from Its Conjugate with Single-Walled Carbon Nanotubes Associated by Pegylated Peptide. Biological and Pharmaceutical Bulletin, 2016, 39, 1687-1693.	0.6	4
25	Development of Novel Drug and Gene Delivery Carriers Composed ofÂSingle-Walled Carbon Nanotubes and Designed Peptides With PEGylation. Journal of Pharmaceutical Sciences, 2016, 105, 2815-2824.	1.6	33
26	Distribution of Silver Nanoparticles to Breast Milk and Their Biological Effects on Breast-Fed Offspring Mice. ACS Nano, 2016, 10, 8180-8191.	7.3	59
27	Tumor growth suppression by the combination of nanobubbles and ultrasound. Cancer Science, 2016, 107, 217-223.	1.7	48
28	Optimization of renal transfection using a renal suction-mediated transfection method in mice. Journal of Drug Targeting, 2016, 24, 450-456.	2.1	6
29	Anti-MUC1 Aptamer/Negatively Charged Amino Acid Dendrimer Conjugates for Targeted Delivery to Human Lung Adenocarcinoma A549 Cells. Biological and Pharmaceutical Bulletin, 2016, 39, 1734-1738.	0.6	22
30	Intravital imaging of live mice at cellular resolution. Drug Delivery System, 2016, 31, 146-153.	0.0	1
31	Development of a Support Vector Machine-Based System to Predict Whether a Compound Is a Substrate of a Given Drug Transporter Using Its Chemical Structure. Journal of Pharmaceutical Sciences, 2016, 105, 2222-2230.	1.6	13
32	Artificial neural network analysis for predicting human percutaneous absorption taking account of vehicle properties. Journal of Toxicological Sciences, 2015, 40, 277-294.	0.7	24
33	Real Time Imaging of Biological Phenomena with Super-duper Luminescent Proteins. Cytologia, 2015, 80, 1-2.	0.2	0
34	Microfluidic devices for construction of contractile skeletal muscle microtissues. Journal of Bioscience and Bioengineering, 2015, 119, 212-216.	1.1	48
35	Long-termin vivogene expression in mouse kidney using i-C31 integrase and electroporation. Journal of Drug Targeting, 2015, 23, 427-435.	2.1	5
36	Modeling and Prediction of Solvent Effect on Human Skin Permeability using Support Vector Regression and Random Forest. Pharmaceutical Research, 2015, 32, 3604-3617.	1.7	21

#	Article	IF	CITATIONS
37	Evaluation of the potential of doxorubicin loaded microbubbles as a theranostic modality using a murine tumor model. Acta Biomaterialia, 2015, 19, 112-118.	4.1	36
38	Development of fluorous lipid-based nanobubbles for efficiently containing perfluoropropane. International Journal of Pharmaceutics, 2015, 487, 64-71.	2.6	21
39	Synthesis and evaluation of glyco-coated liposomes as drug carriers for active targeting in drug delivery systems. Carbohydrate Research, 2015, 405, 78-86.	1.1	13
40	Tumour-associated macrophages targeted transfection with NF-κB decoy/mannose-modified bubble lipoplexes inhibits tumour growth in tumour-bearing mice. Journal of Drug Targeting, 2014, 22, 439-449.	2.1	18
41	Neutralized Nanoparticle Composed of SSâ€Cleavable and pHâ€Activated Lipidâ€Like Material as a Longâ€Lasting and Liverâ€Specific Gene Delivery System. Advanced Healthcare Materials, 2014, 3, 1222-1229.	3.9	35
42	Kidney-selective gene transfection using anionic bubble lipopolyplexes with renal ultrasound irradiation in mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1829-1838.	1.7	16
43	Antitumor effect of nuclear factorâ€pB decoy transfer by mannoseâ€modified bubble lipoplex into macrophages in mouse malignant ascites. Cancer Science, 2014, 105, 1049-1055.	1.7	15
44	Evaluation of inflammatory responses due to small interfering RNA transfer using unmodified- and mannose-modified bubble lipoplexes with ultrasound exposure in primary cultured macrophages. Journal of Drug Targeting, 2014, 22, 732-738.	2.1	3
45	Photothermal ablation of tumor cells using a single-walled carbon nanotube–peptide composite. Journal of Controlled Release, 2014, 173, 59-66.	4.8	104
46	Development of anionic bubble lipopolyplexes for efficient and safe gene transfection with ultrasound exposure in mice. Journal of Controlled Release, 2014, 176, 24-34.	4.8	25
47	Suppression of experimental arthritis with self-assembling glycol-split heparin nanoparticles via inhibition of TLR4–NF-κB signaling. Journal of Controlled Release, 2014, 194, 295-300.	4.8	27
48	Mesoscopic Metal Nanoparticles Doubly Functionalized with Natural and Engineered Lipidic Dispersants for Therapeutics. ACS Nano, 2014, 8, 7370-7376.	7.3	23
49	Self-assembling lipid modified glycol-split heparin nanoparticles suppress lipopolysaccharide-induced inflammation through TLR4–NF-κB signaling. Journal of Controlled Release, 2014, 194, 332-340.	4.8	28
50	Enhancement of the anti-tumor effect of DNA vaccination using an ultrasound-responsive mannose-modified gene carrier in combination with doxorubicin-encapsulated PEGylated liposomes. International Journal of Pharmaceutics, 2014, 475, 401-407.	2.6	27
51	Targeted gene integration using the combination of a sequence-specific DNA-binding protein and phiC31 integrase. Journal of Biotechnology, 2014, 186, 139-147.	1.9	2
52	Ultrasound induced cancer immunotherapy. Advanced Drug Delivery Reviews, 2014, 72, 144-153.	6.6	103
53	Development of PEGylated serum albumin with multiple reduced thiols as a long-circulating scavenger of reactive oxygen species for the treatment of fulminant hepatic failure in mice. Free Radical Biology and Medicine, 2014, 69, 318-323.	1.3	11
54	Preparation of immunostimulatory single-walled carbon nanotube/CpG DNA complexes and evaluation of their potential in cancer immunotherapy. International Journal of Pharmaceutics, 2014, 471, 214-223.	2.6	22

#	Article	IF	Citations
55	Glycosylation-mediated targeting of carriers. Journal of Controlled Release, 2014, 190, 542-555.	4.8	62
56	Inhibition of Cancer Cell Growth by GRP78 siRNA Lipoplex <i>via</i> Activation of Unfolded Protein Response. Biological and Pharmaceutical Bulletin, 2014, 37, 648-653.	0.6	15
57	<i>In Vitro</i> Evaluation of Inhibitory Effect of Nuclear Factor-KappaB Activity by Small Interfering RNA on Pro-tumor Characteristics of M2-Like Macrophages. Biological and Pharmaceutical Bulletin, 2014, 37, 137-144.	0.6	39
58	Liver Suction-Mediated Transfection in Mice Using a Pressure-Controlled Computer System. Biological and Pharmaceutical Bulletin, 2014, 37, 569-575.	0.6	6
59	[Opinion]Expectation for regulatory science. Drug Delivery System, 2014, 29, 188-188.	0.0	0
60	Exclusive Photothermal Heat Generation by a Gadolinium Bis(naphthalocyanine) Complex and Inclusion into Modified High-Density Lipoprotein Nanocarriers for Therapeutic Applications. ACS Nano, 2013, 7, 8908-8916.	7.3	32
61	Automated Extraction of Information on Chemical–P-glycoprotein Interactions from the Literature. Journal of Chemical Information and Modeling, 2013, 53, 2506-2510.	2.5	2
62	Pivotal role of oxidative stress in tumor metastasis under diabetic conditions in mice. Journal of Controlled Release, 2013, 170, 191-197.	4.8	19
63	Pharmacokinetic considerations for targeted drug delivery. Advanced Drug Delivery Reviews, 2013, 65, 139-147.	6.6	111
64	Factors Influencing the Surface Modification of Mesenchymal Stem Cells with Fluorescein-Pegylated Lipids. Biological and Pharmaceutical Bulletin, 2013, 36, 1731-1738.	0.6	11
65	Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro Data. PLoS ONE, 2013, 8, e70330.	1.1	78
66	Structure-Activity Relationship Modeling for Predicting Interactions with Pregnane X Receptor by Recursive Partitioning. Drug Metabolism and Pharmacokinetics, 2012, 27, 506-512.	1.1	5
67	Computer-based Evolutionary Search for a Nonlinear Conversion Function for Establishing In Vitro-In Vivo Correlation (IVIVC) of Oral Drug Formulations. Drug Metabolism and Pharmacokinetics, 2012, 27, 280-285.	1.1	9
68	Bovine Serum Albumin as a Lyoprotectant for Preparation of DNA Dry Powder Formulations Using the Spray-Freeze Drying Method. Biological and Pharmaceutical Bulletin, 2012, 35, 1178-1181.	0.6	10
69	Evaluation of Long-Term Gene Expression in Mouse Liver Using PhiC31 Integrase and Hydrodynamic Injection. Biological and Pharmaceutical Bulletin, 2012, 35, 1182-1186.	0.6	8
70	Luminescent proteins for high-speed single-cell and whole-body imaging. Nature Communications, 2012, 3, 1262.	5.8	247
71	Photodynamic and Photothermal Effects of Semiconducting and Metallic-Enriched Single-Walled Carbon Nanotubes. Journal of the American Chemical Society, 2012, 134, 17862-17865.	6.6	163
72	Development of in vivo gene delivery methods in mice using tissue suction devices for abdominal endoscopic gene therapy. , 2012, , .		0

#	Article	IF	Citations
73	Photothermic regulation of gene expression triggered by laser-induced carbon nanohorns. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7523-7528.	3.3	96
74	Self-assemble gene delivery system for molecular targeting using nucleic acid aptamer. Gene, 2012, 491, 205-209.	1.0	41
75	Creation of Pure Nanodrugs and Their Anticancer Properties. Angewandte Chemie - International Edition, 2012, 51, 10315-10318.	7.2	140
76	In vivo Site-Specific Transfection of Naked Plasmid DNA and siRNAs in Mice by Using a Tissue Suction Device. PLoS ONE, 2012, 7, e41319.	1.1	26
77	Development of a Novel Composite Material with Carbon Nanotubes Assisted by Self-Assembled Peptides Designed in Conjunction with \hat{l}^2 -Sheet Formation. Journal of Pharmaceutical Sciences, 2012, 101, 3398-3412.	1.6	16
78	Efficient suppression of murine intracellular adhesion molecule-1 using ultrasound-responsive and mannose-modified lipoplexes inhibits acute hepatic inflammation. Hepatology, 2012, 56, 259-269.	3.6	41
79	Implantable pneumatically actuated microsystem for renal pressure-mediated transfection in mice. Journal of Controlled Release, 2012, 159, 85-91.	4.8	10
80	Development of Bone-Targeted Catalase Derivatives for Inhibition of Bone Metastasis of Tumor Cells in Mice. Journal of Pharmaceutical Sciences, 2012, 101, 552-557.	1.6	11
81	The involvement of NK cell activation following intranasal administration of CpG DNA lipoplex in the prevention of pulmonary metastasis and peritoneal dissemination in mice. Clinical and Experimental Metastasis, 2012, 29, 63-70.	1.7	11
82	Suppression of Melanoma Growth and Metastasis by DNA Vaccination Using an Ultrasound-Responsive and Mannose-Modified Gene Carrier. Molecular Pharmaceutics, 2011, 8, 543-554.	2.3	68
83	Automated Information Extraction and Structureâ 'Activity Relationship Analysis of Cytochrome P450 Substrates. Journal of Chemical Information and Modeling, 2011, 51, 378-385.	2.5	17
84	Glycosylated carriers for cell-selective and nuclear delivery of nucleic acids. Frontiers in Bioscience - Landmark, 2011, 16, 2970.	3.0	14
85	Intratracheally instilled mannosylated cationic liposome/NFκB decoy complexes for effective prevention of LPS-induced lung inflammation. Journal of Controlled Release, 2011, 149, 42-50.	4.8	54
86	Involvement of activated transcriptional process in efficient gene transfection using unmodified and mannose-modified bubble lipoplexes with ultrasound exposure. Journal of Controlled Release, 2011, 156, 355-363.	4.8	22
87	Development of lysine–histidine dendron modified chitosan for improving transfection efficiency in HEK293 cells. Journal of Controlled Release, 2011, 156, 195-202.	4.8	42
88	Development of a suction device for stabilizing in vivo real-time imaging of murine tissues. Journal of Bioscience and Bioengineering, 2011, 112, 508-510.	1.1	10
89	Polyamidoamine dendrimer-conjugated quantum dots for efficient labeling of primary cultured mesenchymal stem cells. Biomaterials, 2011, 32, 6676-6682.	5.7	53
90	Designing Dendrimers for Drug Delivery and Imaging: Pharmacokinetic Considerations. Pharmaceutical Research, 2011, 28, 1500-1519.	1.7	113

#	Article	IF	Citations
91	Evaluation of Osteoclastogenesis via NFκB Decoy/mannosylated Cationic Liposome-Mediated Inhibition of Pro-inflammatory Cytokine Production from Primary Cultured Macrophages. Pharmaceutical Research, 2011, 28, 742-751.	1.7	15
92	The elucidation of gene transferring mechanism by ultrasound-responsive unmodified and mannose-modified lipoplexes. Biomaterials, 2011, 32, 4659-4669.	5.7	30
93	Comparison of piggyBac transposition efficiency between linear and circular donor vectors in mammalian cells. Journal of Biotechnology, 2011, 154, 205-208.	1.9	9
94	Development of a biochip with serially connected pneumatic balloons for cell-stretching culture. Sensors and Actuators B: Chemical, 2011, 156, 486-493.	4.0	53
95	Key Physiological Phenomena Governing Transgene Expression Based on Tissue Pressure-Mediated Transfection in Mice. Biological and Pharmaceutical Bulletin, 2010, 33, 1627-1632.	0.6	26
96	Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice. Journal of Controlled Release, 2010, 141, 252-259.	4.8	25
97	Î ³ -Polyglutamic acid-coated vectors for effective and safe gene therapy. Journal of Controlled Release, 2010, 142, 404-410.	4.8	81
98	Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective therapeutics. Journal of Controlled Release, 2010, 145, 9-16.	4.8	31
99	Development of an ultrasound-responsive and mannose-modified gene carrier for DNA vaccine therapy. Biomaterials, 2010, 31, 7813-7826.	5.7	85
100	A novel multi-dimensional visualization technique for understanding the design parameters of drug formulations. Computers and Chemical Engineering, 2010, 34, 1306-1311.	2.0	6
101	Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles. Nanomedicine, 2010, 5, 867-879.	1.7	41
102	Anionic Amino Acid Dendrimerâ^'Trastuzumab Conjugates for Specific Internalization in HER2-Positive Cancer Cells. Molecular Pharmaceutics, 2010, 7, 1318-1327.	2.3	55
103	Efficient Gene Transfection by Histidine-Modified Chitosan through Enhancement of Endosomal Escape. Bioconjugate Chemistry, 2010, 21, 1087-1095.	1.8	133
104	Strategies for In Vivo Delivery of siRNAs. BioDrugs, 2010, 24, 195-205.	2.2	105
105	piggyBac Transposon-mediated Long-term Gene Expression in Mice. Molecular Therapy, 2010, 18, 707-714.	3.7	84
106	Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice. Cancer Letters, 2010, 287, 75-81.	3.2	33
107	Improvement of Insulin Resistance by Removal of Systemic Hydrogen Peroxide by PEGylated Catalase in Obese Mice. Molecular Pharmaceutics, 2010, 7, 2069-2076.	2.3	23
108	Size control of lipid-based drug carrier by drug loading. Molecular BioSystems, 2010, 6, 789.	2.9	16

#	Article	IF	CITATIONS
109	Enhanced Transfection Efficiency into Macrophages and Dendritic Cells by a Combination Method Using Mannosylated Lipoplexes and Bubble Liposomes with Ultrasound Exposure. Human Gene Therapy, 2010, 21, 65-74.	1.4	59
110	Immunostimulatory Characteristics Induced by Linear Polyethyleneimine–Plasmid DNA Complexes in Cultured Macrophages. Human Gene Therapy, 2009, 20, 137-145.	1.4	16
111	Oligonuleotide Delivery with Dendritic Poly(L-lysine) for Treatments of the Liver Disorders. Materials Research Society Symposia Proceedings, 2009, 1237, 1.	0.1	O
112	Suppressive effects of sugar-modified cationic liposome/NF-κB decoy complexes on adenovirus vector-induced innate immune responses. Journal of Controlled Release, 2009, 133, 139-145.	4.8	11
113	Encapsulation of the synthetic retinoids Am80 and LE540 into polymeric micelles and the retinoids' release control. Journal of Controlled Release, 2009, 136, 187-195.	4.8	39
114	Prevention of pulmonary metastasis from subcutaneous tumors by binary system-based sustained delivery of catalase. Journal of Controlled Release, 2009, 137, 110-115.	4.8	27
115	Prevention of ischemia/reperfusion injury by hepatic targeting of nitric oxide in mice. Journal of Controlled Release, 2009, 140, 12-17.	4.8	30
116	Mannosylated Cationic Liposomes/CpG DNA Complex for the Treatment of Hepatic Metastasis after Intravenous Administration in Mice. Journal of Pharmaceutical Sciences, 2009, 98, 1193-1197.	1.6	13
117	Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles. International Journal of Pharmaceutics, 2009, 373, 100-106.	2.6	27
118	NFκB decoy delivery using dendritic poly(l-lysine) for treatment of endotoxin-induced hepatitis in mice. Bioorganic and Medicinal Chemistry, 2009, 17, 4990-4995.	1.4	14
119	Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Advanced Drug Delivery Reviews, 2009, 61, 319-326.	6.6	162
120	Pressure-Mediated Transfection of Murine Spleen and Liver. Human Gene Therapy, 2009, 20, 1157-1167.	1.4	20
121	Systematic Research of Peptide Spacers Controlling Drug Release from Macromolecular Prodrug System, Carboxymethyldextran Polyalcoholâ^'Peptideâ^'Drug Conjugates. Bioconjugate Chemistry, 2009, 20, 60-70.	1.8	19
122	Evaluation of proinflammatory cytokine production and liver injury induced by plasmid DNA/cationic liposome complexes with various mixing ratios in mice. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71, 303-309.	2.0	30
123	Enhanced Gene Transfection in Macrophages by Histidine-Conjugated Mannosylated Cationic Liposomes. Biological and Pharmaceutical Bulletin, 2009, 32, 1628-1631.	0.6	20
124	SOD derivatives prevent metastatic tumor growth aggravated by tumor removal. Clinical and Experimental Metastasis, 2008, 25, 531-536.	1.7	31
125	Anti-tumor Effect of All-Trans Retinoic Acid Loaded Polymeric Micelles in Solid Tumor Bearing Mice. Pharmaceutical Research, 2008, 25, 428-434.	1.7	16
126	Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. Journal of Pharmaceutical Sciences, 2008, 97, 726-745.	1.6	124

#	Article	IF	CITATIONS
127	Incorporation of all-trans retinoic acid into lipoplexes inhibits nuclear factor \hat{l}^{Ω} B activation mediated liver injury induced by lipoplexes in mice. Journal of Gene Medicine, 2008, 10, 61-69.	1.4	9
128	Use of mannosylated cationic liposomes/immunostimulatory CpG DNA complex for effective inhibition of peritoneal dissemination in mice. Journal of Gene Medicine, 2008, 10, 392-399.	1.4	23
129	Block copolymer design for stable encapsulation of N-(4-hydroxyphenyl)retinamide into polymeric micelles in mice. International Journal of Pharmaceutics, 2008, 357, 318-322.	2.6	12
130	Pharmacokinetic considerations regarding non-viral cancer gene therapy. Cancer Science, 2008, 99, 856-862.	1.7	19
131	Hydrogen peroxideâ€mediated nuclear factor κB activation in both liver and tumor cells during initial stages of hepatic metastasis. Cancer Science, 2008, 99, 1546-1552.	1.7	26
132	Mannosylated semiconductor quantum dots for the labeling of macrophages. Journal of Controlled Release, 2008, 125, 131-136.	4.8	62
133	Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. Journal of Controlled Release, 2008, 125, 121-130.	4.8	137
134	Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in mice. Journal of Controlled Release, 2008, 126, 274-280.	4.8	20
135	Renal press-mediated transfection method for plasmid DNA and siRNA to the kidney. Biochemical and Biophysical Research Communications, 2008, 372, 383-387.	1.0	38
136	Insertion of nuclear factor-κB binding sequence into plasmid DNA for increased transgene expression in colon carcinoma cells. Journal of Biotechnology, 2008, 133, 36-41.	1.9	9
137	Enhanced Anti-Inflammation of Inhaled Dexamethasone Palmitate Using Mannosylated Liposomes in an Endotoxin-Induced Lung Inflammation Model. Molecular Pharmacology, 2008, 74, 1183-1192.	1.0	67
138	Novel Hierarchical Classification and Visualization Method for Multiobjective Optimization of Drug Properties:  Application to Structureâ^'Activity Relationship Analysis of Cytochrome P450 Metabolism. Journal of Chemical Information and Modeling, 2008, 48, 364-369.	2.5	30
139	Prevention of Hepatic Ischemia/Reperfusion Injury by Prolonged Delivery of Nitric Oxide to the Circulating Blood in Mice. Transplantation, 2008, 85, 264-269.	0.5	30
140	Gene delivery to the lung. Drug Delivery System, 2008, 23, 454-459.	0.0	0
141	Development of cancer immune therapy by cell targeted nucleic acid delivery. Drug Delivery System, 2008, 23, 138-144.	0.0	2
142	Analysis of In Vivo Nuclear Factor-l ^o B Activation during Liver Inflammation in Mice: Prevention by Catalase Delivery. Molecular Pharmacology, 2007, 71, 446-453.	1.0	20
143	Targeted Delivery Systems of Small Interfering RNA by Systemic Administration. Drug Metabolism and Pharmacokinetics, 2007, 22, 142-151.	1.1	94
144	Relationship between Drug Release of DE-310, Macromolecular Prodrug of DX-8951f, and Cathepsins Activity in Several Tumors. Biological and Pharmaceutical Bulletin, 2007, 30, 2365-2370.	0.6	42

#	Article	IF	Citations
145	Development of Nitric Oxide Donors for the Treatment of Cardiovascular Diseases. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2007, 5, 204-208.	0.4	42
146	Automated Extraction of Information from the Literature on Chemical-CYP3A4 Interactions. Journal of Chemical Information and Modeling, 2007, 47, 2449-2455.	2.5	13
147	The potential role of fucosylated cationic liposome/NFκB decoy complexes in the treatment of cytokine-related liver disease. Biomaterials, 2007, 28, 532-539.	5.7	43
148	Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes. Biomaterials, 2007, 28, 3255-3262.	5.7	86
149	Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials, 2007, 28, 1434-1442.	5.7	130
150	Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. International Journal of Pharmaceutics, 2007, 329, 192-198.	2.6	61
151	Novel histidine-conjugated galactosylated cationic liposomes for efficient hepatocyte-selective gene transfer in human hepatoma HepG2 cells. Journal of Controlled Release, 2007, 118, 262-270.	4.8	77
152	Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes. Journal of Controlled Release, 2007, 119, 262-270.	4.8	43
153	Inhibition of peritoneal dissemination of tumor cells by cationized catalase in mice. Journal of Controlled Release, 2007, 119, 121-127.	4.8	20
154	Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol. Journal of Controlled Release, 2007, 119, 271-278.	4.8	20
155	Efficient protection by cationized catalase against H2O2 injury in primary cultured alveolar epithelial cells. Journal of Controlled Release, 2007, 121, 74-80.	4.8	10
156	Cationized catalase-loaded hydrogel for growth inhibition of peritoneally disseminated tumor cells. Journal of Controlled Release, 2007, 122, 151-158.	4.8	16
157	Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 1290-1296.	1.4	4
158	Hepatocyte-Selective Gene Transfer by Galactosylated Protein/Linear Polyethyleneimine/Plasmid DNA Complexes in Mice. Journal of Biomedical Nanotechnology, 2007, 3, 277-284.	0.5	6
159	Basic fibroblast growth factor-binding peptide as a novel targeting ligand of drug carrier to tumor cells. Journal of Drug Targeting, 2006, 14, 536-545.	2.1	33
160	Quantitative structure/activity relationship modelling of pharmacokinetic properties using genetic algorithm-combined partial least squares method. Journal of Drug Targeting, 2006, 14, 496-504.	2.1	11
161	Inhibition of tumour metastasis by targeted delivery of antioxidant enzymes. Expert Opinion on Drug Delivery, 2006, 3, 355-369.	2.4	40
162	Visualization of Large-Scale Aqueous Solubility Data Using a Novel Hierarchical Data Visualization Technique. Journal of Chemical Information and Modeling, 2006, 46, 1054-1059.	2.5	18

#	Article	IF	Citations
163	Intravenous administration of mannosylated cationic liposome/NFκB decoy complexes effectively prevent LPS-induced cytokine production in a murine liver failure model. FEBS Letters, 2006, 580, 3706-3714.	1.3	34
164	Influence of Cholesterol Composition on the Association of Serum Mannan-Binding Proteins with Mannosylated Liposomes. Biological and Pharmaceutical Bulletin, 2006, 29, 613-618.	0.6	6
165	Role of Tyrosine and Tryptophan in Chemically Modified Serum Albumin on Its Tissue Distribution. Biological and Pharmaceutical Bulletin, 2006, 29, 1926-1930.	0.6	2
166	Effect of the Particle Size of Galactosylated Lipoplex on Hepatocyte-Selective Gene Transfection after Intraportal Administration. Biological and Pharmaceutical Bulletin, 2006, 29, 1521-1523.	0.6	30
167	Intracellular Trafficking Is the Important Process That Determines the Optimal Charge Ratio on Transfection by Galactosylated Lipoplex in HepG2 Cells. Biological and Pharmaceutical Bulletin, 2006, 29, 1986-1990.	0.6	11
168	Analysis of the molecular interaction between mannosylated proteins and serum mannan-binding lectins. International Journal of Pharmaceutics, 2006, 316, 117-123.	2.6	6
169	Inhibition of liver metastasis by all-trans retinoic acid incorporated into O/W emulsions in mice. International Journal of Pharmaceutics, 2006, 321, 42-49.	2.6	31
170	Analysis of the molecular interaction of glycosylated proteins with rabbit liver asialoglycoprotein receptors using surface plasmon resonance spectroscopy. Journal of Pharmaceutical and Biomedical Analysis, 2006, 41, 966-972.	1.4	5
171	Inhibition of adhesion and proliferation of peritoneally disseminated tumor cells by pegylated catalase. Clinical and Experimental Metastasis, 2006, 23, 269-278.	1.7	27
172	PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. Free Radical Biology and Medicine, 2006, 41, 1449-1458.	1.3	52
173	Liver targeting of catalase by cationization for prevention of acute liver failure in mice. Journal of Controlled Release, 2006, 110, 273-282.	4.8	38
174	Induction of apoptosis in A549 human lung cancer cells by all-trans retinoic acid incorporated in DOTAP/cholesterol liposomes. Journal of Controlled Release, 2006, 110, 514-521.	4.8	48
175	Improved anti-oxidant activity of superoxide dismutase by direct chemical modification. Journal of Controlled Release, 2006, 111, 204-211.	4.8	15
176	Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. Journal of Controlled Release, 2006, 111, 333-342.	4.8	182
177	Effect of mannose density on mannose receptor-mediated cellular uptake of mannosylated O/W emulsions by macrophages. Journal of Controlled Release, 2006, 114, 193-201.	4.8	77
178	Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. Journal of Controlled Release, 2006, 114, 69-77.	4.8	105
179	Incorporation into a biodegradable hyaluronic acid matrix enhances in vivo efficacy of recombinant human interleukin 11 (rhlL11). Journal of Controlled Release, 2006, 115, 134-139.	4.8	9
180	Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex. Journal of Controlled Release, 2006, 115, 226-233.	4.8	44

#	Article	IF	Citations
181	Inhibition of pulmonary metastasis in mice by all-trans retinoic acid incorporated in cationic liposomes. Journal of Controlled Release, 2006, 116, 58-63.	4.8	35
182	PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice. Journal of Controlled Release, 2006, 116, 330-336.	4.8	124
183	Use of lipoplex-induced nuclear factor-l ^o B activation to enhance transgene expression by lipoplex in mouse lung. Journal of Gene Medicine, 2006, 8, 53-62.	1.4	36
184	Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration. Journal of Gene Medicine, 2006, 8, 824-834.	1.4	56
185	Efficient Gene Transfer into Macrophages and Dendritic Cells by in Vivo Gene Delivery with Mannosylated Lipoplex via the Intraperitoneal Route. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 828-834.	1.3	64
186	Evaluation of Proinflammatory Cytokine Production Induced by Linear and Branched Polyethylenimine/Plasmid DNA Complexes in Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 1382-1390.	1.3	95
187	Lipid Carrier Systems for Targeted Drug and Gene Delivery. Chemical and Pharmaceutical Bulletin, 2005, 53, 871-880.	0.6	86
188	Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells. International Journal of Pharmaceutics, 2005, 301, 255-261.	2.6	28
189	Theoretical considerations involving the pharmacokinetics of plasmid DNA. Advanced Drug Delivery Reviews, 2005, 57, 675-688.	6.6	34
190	Cationic charge-dependent hepatic delivery of amidated serum albumin. Journal of Controlled Release, 2005, 102, 583-594.	4.8	64
191	Intracellular distribution of NFκB decoy and its inhibitory effect on TNFα production by LPS stimulated RAW 264.7 cells. Journal of Controlled Release, 2005, 107, 373-382.	4.8	11
192	The role of dioleoylphosphatidylethanolamine (DOPE) in targeted gene delivery with mannosylated cationic liposomes via intravenous route. Journal of Controlled Release, 2005, 108, 484-495.	4.8	90
193	Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. Journal of Controlled Release, 2005, 109, 101-107.	4.8	65
194	Enhanced gene expression in lung by a stabilized lipoplex using sodium chloride for complex formation. Journal of Gene Medicine, 2005, 7, 1526-1533.	1.4	30
195	Effect of Galactose Density on Asialoglycoprotein Receptor-Mediated Uptake of Galactosylated Liposomes. Journal of Pharmaceutical Sciences, 2005, 94, 2266-2275.	1.6	82
196	Biodistribution characteristics of all-trans retinoic acid incorporated in liposomes and polymeric micelles following intravenous administration. Journal of Pharmaceutical Sciences, 2005, 94, 2606-2615.	1.6	40
197	Tissue-Specific Characteristics of in Vivo Electric Gene: Transfer by Tissue and Intravenous Injection of Plasmid DNA. Pharmaceutical Research, 2005, 22, 883-891.	1.7	38
198	Development of Polyethylene Glycol-Conjugated Poly-S-Nitrosated Serum Albumin, a Novel S-Nitrosothiol for Prolonged Delivery of Nitric Oxide in the Blood Circulation in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 1117-1124.	1.3	51

#	Article	IF	Citations
199	Interaction with Blood Components Plays a Crucial Role in Asialoglycoprotein Receptor-Mediated in Vivo Gene Transfer by Galactosylated Lipoplex. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 484-493.	1.3	29
200	Biodistribution characteristics of mannosylated and fucosylated O/W emulsions in mice. Journal of Drug Targeting, 2005, 13, 479-487.	2.1	25
201	Tissue and intrahepatic distribution and subcellular localization of a mannosylated lipoplex after intravenous administration in mice. Journal of Controlled Release, 2004, 98, 157-167.	4.8	26
202	Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice. Clinical and Experimental Metastasis, 2004, 21, 213-221.	1.7	59
203	Biodistribution Characteristics of Galactosylated Emulsions and Incorporated Probucol for Hepatocyte-Selective Targeting of Lipophilic Drugs in Mice. Pharmaceutical Research, 2004, 21, 932-939.	1.7	27
204	Inhibition of Metastatic Tumor Growth in Mouse Lung by Repeated Administration of Polyethylene Glycol-Conjugated Catalase. Clinical Cancer Research, 2004, 10, 7685-7691.	3.2	72
205	Physicochemical, tissue distribution, and vasodilation characteristics of nitrosated serum albumin: delivery of nitric oxide in vivo. Journal of Pharmaceutical Sciences, 2004, 93, 2343-2352.	1.6	18
206	Two†and threeâ€dimensional QSAR of carrierâ€mediated transport of βâ€lactam antibiotics in Cacoâ€2 cells. Journal of Pharmaceutical Sciences, 2004, 93, 3057-3065.	1.6	18
207	Uptake characteristics of mannosylated and fucosylated bovine serum albumin in primary cultured rat sinusoidal endothelial cells and Kupffer cells. International Journal of Pharmaceutics, 2004, 287, 147-154.	2.6	43
208	Enhanced hepatocyte-selective in vivo gene expression by stabilized galactosylated liposome/plasmid DNA complex using sodium chloride for complex formation. Molecular Therapy, 2004, 10, 719-729.	3.7	63
209	Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochemical and Biophysical Research Communications, 2004, 317, 992-999.	1.0	99
210	In Silico Approaches for Predicting ADME Properties of Drugs. Drug Metabolism and Pharmacokinetics, 2004, 19, 327-338.	1.1	162
211	QSAR analysis of the inhibition of recombinant CYP 3A4 activity by structurally diverse compounds using a genetic algorithm-combined partial least squares method. Pharmaceutical Research, 2003, 20, 1401-1408.	1.7	42
212	Analysis of hepatic disposition of galactosylated cationic liposome/plasmid DNA complexes in perfused rat liver. Pharmaceutical Research, 2003, 20, 1452-1459.	1.7	38
213	Mechanistic and empirical modeling of skin permeation of drugs. Advanced Drug Delivery Reviews, 2003, 55, 1185-1199.	6.6	74
214	Targeted and sustained drug delivery using PEGylated galactosylated liposomes. International Journal of Pharmaceutics, 2003, 266, 77-84.	2.6	54
215	Therapeutic effect of intravenous delivery of lipoplexes containing the interferon- \hat{l}^2 gene and poly I: poly C in a murine lung metastasis model. Cancer Gene Therapy, 2003, 10, 661-668.	2.2	49
216	Molecular weight-dependent gene transfection activity of unmodified and galactosylated polyethyleneimine on hepatoma cells and mouse liver. Molecular Therapy, 2003, 7, 254-261.	3.7	163

#	Article	IF	Citations
217	Analysis of Hepatic Disposition of Native and Galactosylated Polyethylenimine Complexed with Plasmid DNA in Perfused Rat Liver. Drug Metabolism and Pharmacokinetics, 2003, 18, 230-237.	1.1	11
218	Pharmacokinetic Analysis of in Vivo Disposition of Succinylated Proteins Targeted to Liver Nonparenchymal Cells via Scavenger Receptors: Importance of Molecular Size and Negative Charge Density for in Vivo Recognition by Receptors. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 467-477.	1.3	57
219	Nonviral Approaches Satisfying Various Requirements for Effective in Vivo Gene Therapy Biological and Pharmaceutical Bulletin, 2002, 25, 275-283.	0.6	101
220	Prediction of Human Skin Permeability Using a Combination of Molecular Orbital Calculations and Artificial Neural Network Biological and Pharmaceutical Bulletin, 2002, 25, 361-366.	0.6	55
221	Plasmid DNA activates murine macrophages to induce inflammatory cytokines in a CpG motif-independent manner by complex formation with cationic liposomes. Biochemical and Biophysical Research Communications, 2002, 293, 344-348.	1.0	70
222	Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers. Journal of Controlled Release, 2002, 80, 283-294.	4.8	63
223	Important role of serum proteins associated on the surface of particles in their hepatic disposition. Journal of Controlled Release, 2002, 83, 89-96.	4.8	32
224	Quantitative structure/property relationship analysis of Cacoâ€2 permeability using a genetic algorithmâ€based partial least squares method. Journal of Pharmaceutical Sciences, 2002, 91, 2230-2239.	1.6	52
225	Inhibition of experimental pulmonary metastasis by controlling biodistribution of catalase in mice. International Journal of Cancer, 2002, 99, 474-479.	2.3	69
226	Prediction of Caco-2 cell permeability using a combination of MO-calculation and neural network. International Journal of Pharmaceutics, 2002, 237, 95-105.	2.6	58
227	Targeting efficiency of galactosylated liposomes to hepatocytes in vivo: effect of lipid composition. Pharmaceutical Research, 2002, 19, 1808-1814.	1.7	56
228	Pharmacokinetics and preventive effects of targeted catalase derivatives on hydrogen peroxide-induced injury in perfused rat liver. Pharmaceutical Research, 2002, 19, 1815-1821.	1.7	23
229	Glycosylated Cationic Liposomes for Cell-Selective Gene Delivery. Critical Reviews in Therapeutic Drug Carrier Systems, 2002, 19, 171-190.	1.2	55
230	Factors Affecting Drug and Gene Delivery: Effects of Interaction with Blood Components. Critical Reviews in Therapeutic Drug Carrier Systems, 2002, 19, 191-234.	1.2	93
231	Pharmacokinetic Analysis of Lectin-dependent Biodistribution of Fucosylated Bovine Serum Albumin: A Possible Carrier for Kupffer Cells. Journal of Drug Targeting, 2001, 9, 341-351.	2.1	28
232	Enhanced Gene Transfection in Macrophages Using Mannosylated Cationic Liposome-Polyethylenimine-Plasmid DNA Complexes. Journal of Drug Targeting, 2001, 9, 201-207.	2.1	42
233	In vivo recognition of mannosylated proteins by hepatic mannose receptors and mannan-binding protein. American Journal of Physiology - Renal Physiology, 2001, 280, G879-G889.	1.6	35
234	Novel Galactosylated Liposomes for Hepatocyteâ€Selective Targeting of Lipophilic Drugs. Journal of Pharmaceutical Sciences, 2001, 90, 105-113.	1.6	65

#	Article	IF	Citations
235	Cell-specific delivery of genes with glycosylated carriers. Advanced Drug Delivery Reviews, 2001, 52, 187-196.	6.6	173
236	Synthesis and pharmacological activity of a novel water-soluble hepatocyte-specific polymeric prodrug of prostaglandin E 1 using lactosylated poly(l-glutamic hydrazide) as a carrier 1 1Abbreviations: PGE1, prostaglandin E1; PLGA-HZ, poly(l-glutamic hydrazide); Lac-NH-PLGA, lactosylated poly(l-glutamic hydrazide); PGE1 conjugate, prostaglandin E1 prodrug using Lac-NH-PLGA as a carrier; DTPA anhydride, diethylenetriamine-N,N,N′,N″,N″-pentaacetic dianhydride; GPT, glutamic pyruvic	2.0	24
237	transaminase; AUC, area und. Biochemical Pharmacology, 2001, 62, 1531-1536. Disposition characteristics of emulsions and incorporated drugs after systemic or local injection. Advanced Drug Delivery Reviews, 2000, 45, 77-88.	6.6	60
238	Controlled biodistribution of galactosylated liposomes and incorporated probucol in hepatocyte-selective drug targeting. Journal of Controlled Release, 2000, 69, 369-377.	4.8	55
239	Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression. Journal of Controlled Release, 2000, 66, 255-269.	4.8	160
240	In vivo gene delivery to the liver using novel galactosylated cationic liposomes. Pharmaceutical Research, 2000, 17, 306-313.	1.7	155
241	Targeted Delivery of Prostaglandin E ₁ to Hepatocytes Using Galactosylated Liposomes. Journal of Drug Targeting, 2000, 8, 137-142.	2.1	23
242	Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice. Biochimica Et Biophysica Acta - General Subjects, 2000, 1524, 258-265.	1.1	113
243	Pharmacokinetics and <i>In Vivo < li>Gene Transfer of Plasmid DNA Complexed with Mannosylated Poly(L-Lysine) in Mice. Journal of Drug Targeting, 2000, 8, 29-38.</i>	2.1	51
244	Pharmacokinetic Evaluation of Mannosylated Bovine Serum Albumin as a Liver Cell-Specific Carrier: Quantitative Comparison with Other Hepatotropic Ligands. Journal of Drug Targeting, 1999, 6, 349-360.	2.1	35
245	Disposition of radioactivity after injection of liver-targeted proteins labeled with 111In or 125I. Effect of labeling on distribution and excretion of radioactivity in rats. Journal of Pharmaceutical Sciences, 1999, 88, 577-585.	1.6	24
246	Characterization of plasmid DNA binding and uptake by peritoneal macrophages from class A scavenger receptor knockout mice. Pharmaceutical Research, 1999, 16, 503-508.	1.7	52
247	Hepatic uptake of polystyrene microspheres in rats: Effect of particle size on intrahepatic distribution. Journal of Controlled Release, 1999, 59, 15-22.	4.8	119
248	Design of polymeric prodrugs of prostaglandin E1 having galactose residue for hepatocyte targeting. Journal of Controlled Release, 1999, 62, 253-262.	4.8	45
249	Mechanisms of hepatic disposition of polystyrene microspheres in rats: Effects of serum depend on the sizes of microspheres. Journal of Controlled Release, 1999, 61, 241-250.	4.8	30
250	Hepatocyte-specific distribution of catalase and its inhibitory effect on hepatic ischemia/reperfusion injury in mice. Free Radical Research, 1999, 30, 265-274.	1.5	34
251	Liver uptake and hepato-biliary transfer of galactosylated proteins in rats are determined by the extent of galactosylation. Biochimica Et Biophysica Acta - General Subjects, 1999, 1427, 183-192.	1.1	18
252	Pharmacokinetic Evaluation of Biodistribution Data Obtained with Radiolabeled Proteins in Mice Biological and Pharmaceutical Bulletin, 1999, 22, 214-218.	0.6	14

#	Article	IF	CITATIONS
253	Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharmaceutical Research, 1998, 15, 128-132.	1.7	125
254	Extravasation of macromolecules. Advanced Drug Delivery Reviews, 1998, 34, 93-108.	6.6	122
255	Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injection. Journal of Controlled Release, 1998, 52, 239-252.	4.8	48
256	Targeted delivery of plasmid DNA complexed with galactosylated poly(I-lysine). Journal of Controlled Release, 1998, 53, 301-310.	4.8	141
257	Disposition Characteristics of Glycosylated Poly(amino acids) as Liver Cell-Specific Drug Carrier. Journal of Drug Targeting, 1998, 6, 229-239.	2.1	23
258	Involvement of Specific Mechanism in Plasmid DNA Uptake by Mouse Peritoneal Macrophages. Biochemical and Biophysical Research Communications, 1998, 245, 729-733.	1.0	70
259	Asialoglycoprotein Receptor-Mediated Gene Transfer Using Novel Galactosylated Cationic Liposomes. Biochemical and Biophysical Research Communications, 1998, 252, 78-83.	1.0	161
260	Control of Plasma Cholesterol-Lowering Action of Probucol with Various Lipid Carrier Systems Biological and Pharmaceutical Bulletin, 1998, 21, 492-497.	0.6	21
261	Development of Targeted Delivery Systems for Nucleic Acid Drugs. Journal of Drug Targeting, 1997, 4, 337-357.	2.1	53
262	Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(I-lysine). Biochemical Pharmacology, 1997, 53, 887-895.	2.0	91
263	Augmented inhibitory effect of superoxide dismutase on superoxide anion release from macrophages by direct cationization. Biochimica Et Biophysica Acta - General Subjects, 1997, 1335, 91-98.	1.1	9
264	Targeted delivery of drugs and proteins to the liver via receptor-mediated endocytosis. Journal of Controlled Release, 1997, 46, 129-137.	4.8	45
265	In vivo evaluation of acyclovir prodrug penetration and metabolism through rat skin using a diffusion/bioconversion model. Pharmaceutical Research, 1997, 14, 56-62.	1.7	19
266	Renal disposition of recombinant human interleukin-11 in the isolated perfused rat kidney. Pharmaceutical Research, 1997, 14, 86-90.	1.7	8
267	Pharmacokinetic analysis of scavenger receptor-mediated uptake of anionized proteins in the isolated perfused rat liver. International Journal of Pharmaceutics, 1997, 151, 15-26.	2.6	12
268	Nonviral Vectors for In Vivo Gene Delivery: Physicochemical and Pharmacokinetic Considerations. Critical Reviews in Therapeutic Drug Carrier Systems, 1997, 14, 40.	1.2	101
269	Mannosylated Superoxide Dismutase Inhibits Hepatic Reperfusion Injury in Rats. Journal of Surgical Research, 1996, 60, 36-40.	0.8	25
270	Control of pharmacokinetic profiles of drugâ€"macromolecule conjugates. Advanced Drug Delivery Reviews, 1996, 19, 377-399.	6.6	49

#	Article	IF	CITATIONS
271	Theoretical design of prodrug-enhancer combination based on a skin diffusion model: prediction of permeation of acyclovir prodrugs treated with 1-geranylazacycloheptan-2-one. Pharmaceutical Research, 1996, 13, 427-432.	1.7	18
272	Development and pharmacokinetics of galactosylated poly-L-glutamic acid as a biodegradable carrier for liver-specific drug delivery. Pharmaceutical Research, 1996, 13, 880-884.	1.7	50
273	Disposition characteristics of plasmid DNA in the single-pass rat liver perfusion system. Pharmaceutical Research, 1996, 13, 599-603.	1.7	60
274	Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharmaceutical Research, 1996, 13, 820-831.	1.7	205
275	Pharmacokinetic evaluation of polymeric carriers. Advanced Drug Delivery Reviews, 1996, 21, 135-155.	6.6	65
276	Uptake Characteristics of Oligonucleotides in the Isolated Rat Liver Perfusion System. Oligonucleotides, 1996, 6, 177-183.	4.4	32
277	Stability and Pharmacokinetic Characteristics of Oligonucleotides Modified at Terminal Linkages in Mice. Antisense Research and Development, 1995, 5, 115-121.	3.3	43
278	Renal Disposition Characteristics of Oligonucleotides Modified at Terminal Linkages in the Perfused Rat Kidney. Antisense Research and Development, 1995, 5, 279-287.	3.3	37
279	Physicochemical and Pharmacokinetic Characteristics of Plasmici DNA/ Cationic Liposome Complexes. Journal of Pharmaceutical Sciences, 1995, 84, 1267-1271.	1.6	152
280	Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Critical Reviews in Oncology/Hematology, 1995, 18, 207-231.	2.0	113
281	Hepatic targeting of drugs and proteins by chemical modification. Journal of Controlled Release, 1995, 36, 99-107.	4.8	25
282	Design for cell-specific targeting of proteins utilizing sugar-recognition mechanism: effect of molecular weight of proteins on targeting efficiency. Pharmaceutical Research, 1995, 12, 209-214.	1.7	39
283	The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharmaceutical Research, 1995, 12, 825-830.	1.7	403
284	In Vivo Disposition Characteristics of Plasmid DNA Complexed with Cationic Liposomes. Journal of Drug Targeting, 1995, 3, 149-157.	2.1	108
285	Improvement of Therapeutic Effect of Human Recombinant Superoxide Dismutase on Ischemic Acute Renal Failure in the Rat via Cationization and Conjugation with Polyethylene Glycol. Journal of Drug Targeting, 1994, 2, 317-321.	2.1	29
286	Control of <i>In Vivo </i> Fate of Albumin Derivatives Utilizing Combined Chemical Modification. Journal of Drug Targeting, 1994, 2, 157-165.	2.1	45
287	Pharmacokinetics in design of polymeric drug delivery systems. Journal of Controlled Release, 1994, 31, 163-171.	4.8	32
288	Targeted delivery of superoxide dismutase to macrophages via mannose receptor-mediated mechanism. Biochemical Pharmacology, 1994, 47, 853-858.	2.0	47

#	Article	IF	CITATIONS
289	Skin Penetration Enhancement of Acyclovir by Prodrug-Enhancer Combination Biological and Pharmaceutical Bulletin, 1994, 17, 1141-1143.	0.6	14
290	Long Circulating Emulsion Carrier Systems for Highly Lipophilic Drugs Biological and Pharmaceutical Bulletin, 1994, 17, 121-125.	0.6	132
291	Manipulation of Renal Disposition of Human Recombinant Superoxide Dismutase by Chemical Modification Biological and Pharmaceutical Bulletin, 1994, 17, 296-301.	0.6	26
292	Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting. Pharmaceutical Research, 1993, 10, 1253-1261.	1.7	77
293	Disposition characteristics of protein drugs in the perfused rat kidney. Pharmaceutical Research, 1993, 10, 823-827.	1.7	26
294	Controlled Biodistribution of Highly Lipophilic Drugs with Various Parenteral Formulations. Journal of Drug Targeting, 1993, 1, 117-124.	2.1	46
295	Analysis of Skin Penetration Enhancement Based on a Two-Layer Skin Diffusion Model with Polar and Nonpolar Routes in the Stratum Corneum: Dose-Dependent Effect of 1-Geranylazacycloheptan-2-one on Drugs with Different Lipophilicities Biological and Pharmaceutical Bulletin, 1993, 16, 690-697.	0.6	53
296	Disposition Characteristics of Model Macromolecules in the Perfused Rat Kidney Biological and Pharmaceutical Bulletin, 1993, 16, 158-162.	0.6	18
297	Preparation and properties of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate. Bioconjugate Chemistry, 1992, 3, 132-137.	1.8	44
298	Therapeutic effects of superoxide dismutase derivatives modified with mono- or polysaccharides on hepatic injury induced by ischemia/reperfusion. Biochemical and Biophysical Research Communications, 1992, 189, 191-196.	1.0	91
299	Pharmacokinetic analysis of drug absorption from muscle based on a physiological diffusion model: effect of molecular size on absorption. Pharmaceutical Research, 1992, 09, 161-168.	1.7	22
300	Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice. International Journal of Pharmaceutics, 1992, 85, 75-85.	2.6	70
301	Pharmacokinetic analysis of uptake process of lactosaminated albumin in rat liver constant infusion experiments. International Journal of Pharmaceutics, 1992, 80, 101-108.	2.6	15
302	Assessment of drug disposition in the perfused rat brain by statistical moment analysis. Pharmaceutical Research, 1991, 08, 683-689.	1.7	9
303	Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharmaceutical Research, 1991, 08, 437-444.	1.7	69
304	Hepatic disposition characteristics of 111 In-labeled lactosaminated bovine serum albumin in rats. Pharmaceutical Research, 1991, 08, 1253-1257.	1.7	15
305	Tumor Localization andin vivoAntitumor Activity of the Immunoconjugate Composed of Anti-human Colon Cancer Monoclonal Antibody and Mitomycin C-Dextran Conjugate. Japanese Journal of Cancer Research, 1991, 82, 219-226.	1.7	26
306	Statistical moments and disposition parameters in a local perfusion system under mammillary nonequilibrium condition. Journal of Pharmacokinetics and Pharmacodynamics, 1990, 18, 449-458.	0.6	4

#	Article	IF	CITATIONS
307	Disposition characteristics of macromolecules in tumor-bearing mice. Pharmaceutical Research, 1990, 07, 339-346.	1.7	207
308	Soluble macromolecular carriers for the delivery of antitumour drugs. Advanced Drug Delivery Reviews, 1989, 3, 247-266.	6.6	55
309	Analysis of drug penetration through the skin by the two-layer skin model. Pharmaceutical Research, 1989, 06, 931-937.	1.7	41
310	Statistical moment analysis of hepatobiliary transport of phenol red in the perfused rat liver. Pharmaceutical Research, 1989, 06, 140-146.	1.7	34
311	Structure–Activity Relationship of 1-Alkyl- or 1 -Alkenylazacycloal kanone Derivatives as Percutaneous Penetration Enhancers. Journal of Pharmaceutical Sciences, 1988, 77, 418-424.	1.6	113
312	Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular administration. International Journal of Pharmaceutics, 1987, 37, 145-154.	2.6	67
313	Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharmaceutical Research, 1987, 04, 293-300.	1.7	163
314	A new method for assessment of drug disposition in muscle: Application of statistical moment theory to local perfusion systems. Journal of Pharmacokinetics and Pharmacodynamics, 1985, 13, 609-631.	0.6	62
315	Regeneration characteristics of mitomycin C-dextran conjugate in relation to its activity Chemical and Pharmaceutical Bulletin, 1983, 31, 2055-2063.	0.6	61
316	Effect of complexation with dextran sulfate on the lymphatic delivery of bleomycin following intrastitial administration Journal of Pharmacobio-dynamics, 1979, 2, 383-390.	0.5	8
317	Targeted Gene Delivery: Importance of Administration Routes. , 0, , .		7